March 22, 2010 (FinancialWire) — Valeant Pharmaceuticals International (NYSE: VRX) said it has signed a binding agreement to acquire a private branded generics and over the counter company located in Brazil for around $28 million.

Valeant said that a large portion of the company's product portfolio is in dermatology and the company had annual sales of around $19 million in 2009.

It added that, over the past five years, this company has delivered a compound annual growth rate of nearly 15%.

In a separate transaction, Valeant will acquire a new 165,000 square foot manufacturing plant approved to produce solids, semi-solids and liquids for approximately $28 million. Both transactions, which are subject to customary closing conditions, are expected to close in the second quarter of 2010 and will be collectively accretive to Valeant in 2010.

"We are excited to advance our dermatology presence in the Brazilian market, which is one of the leading dermatology markets worldwide," stated J. Michael Pearson, chairman and chief executive officer. "This acquisition gets us closer to building the critical mass we need in the Brazilian pharmaceutical market. The new state of the art manufacturing plant will allow us to close our current subscale manufacturing facility and eliminates the need for any third party manufacturers the combination of which should allow us to significantly improve margins."

California-based

Valeant Pharmaceuticals International is a specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products primarily in the areas of neurology and dermatology.  

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.